Not yet recruitingInterventionalPhase 2Last updated Aug 10, 2026

A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes

A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Study Assessing the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes Mellitus.

Overview

ClinicalTrials.gov ID: NCT07755150
Lead Sponsor: Chendu DIAO Pharmaceutical Group CO., LTD.INDUSTRY
Brief Summary: This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study aims to assess the efficacy, safety, and PK characteristics of DA-302168S tablets in Chinese T2DM participants, and to provide dose-selection evidence for the Phase III confirmatory trial.
Study Type

Status

Overall Status: Not yet recruiting
Start Date: Aug 30, 2026Estimated
Primary Completion Date: Oct 20, 2027Estimated
Completion Date: Oct 20, 2027Estimated

Study Record Dates

First Submitted: Aug 5, 2026
First Submitted that Met QC Criteria: Aug 5, 2026
First Posted: Aug 10, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 5, 2026
Last Update Posted: Aug 10, 2026Actual
Last Verified: Aug 2026

NCT06953063Completed

A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects

NCT06481085Completed

To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

NCT07229534Not yet recruiting

Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes

NCT07321678Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

NCT06534320Completed

Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of DA-302168S Tablets

NCT07239440Not yet recruiting

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control